Atom Investors’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-33,539
Closed -$4.84M 689
2025
Q3
$4.84M Buy
33,539
+4,113
+14% +$561K 0.37% 78
2025
Q2
$3.72M Buy
29,426
+6,904
+31% +$848K 0.33% 79
2025
Q1
$2.88M Buy
22,522
+875
+4% +$119K 0.35% 83
2024
Q4
$2.86M Sell
21,647
-470
-2% -$66.1K 0.36% 92
2024
Q3
$3.22M Sell
22,117
-70
-0.3% -$10.1K 0.34% 98
2024
Q2
$3.05M Buy
22,187
+1,474
+7% +$197K 0.3% 111
2024
Q1
$2.84M Buy
20,713
+4,445
+27% +$607K 0.35% 83
2023
Q4
$2.21M Buy
16,268
+3,448
+27% +$421K 0.39% 78
2023
Q3
$1.57M Buy
12,820
+319
+3% +$40.6K 0.36% 82
2023
Q2
$1.59M Sell
12,501
-66,000
-84% -$8.57M 0.6% 32
2023
Q1
$10.1M Sell
78,501
-3,187
-4% -$417K 5.52% 1
2022
Q4
$10.7M Sell
81,688
-12,391
-13% -$1.6M 5.36% 2
2022
Q3
$11M Sell
94,079
-20,921
-18% -$2.6M 3.87% 2
2022
Q2
$13.5M Sell
115,000
-37,592
-25% -$4.46M 5.91% 3
2022
Q1
$19.9M Sell
152,592
-97,917
-39% -$12.8M 9.3% 1
2021
Q4
$38.2M Buy
250,509
+27,780
+12% +$4.3M 6.41% 4
2021
Q3
$36M Sell
222,729
-10,133
-4% -$1.71M 2.92% 6
2021
Q2
$38.1M Buy
232,862
+176,449
+313% +$27.2M 4.79% 4
2021
Q1
$8.49M Buy
+56,413
New +$8.96M 1.42% 19

Other funds holding IBB

Atom Investors's IBB Position: Q4 2025 in Review

Atom Investors sold out of iShares Biotechnology ETF (IBB) in Q4 2025, closing a stake of 33,539 shares — an estimated $4.84M sold.

Atom Investors first reported a position in IBB in Q1 2021 and held it in 19 quarters. The position peaked at $38.2M in Q4 2021. 955 funds tracked by Wall St. Rank hold IBB as of Q4 2025.

  • Atom Investors reported no remaining iShares Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 33,539 iShares Biotechnology ETF shares in Q4 2025, an estimated $4.84M.
  • Atom Investors first reported a position in iShares Biotechnology ETF in Q1 2021 and held it in 19 quarters.
  • Atom Investors's iShares Biotechnology ETF position peaked at $38.2M in Q4 2021.
  • 955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.